




7 July 2005

Ark Therapeutics Group Plc
79 New Cavendish Street
London W1W 6XB
Tel: +44 (0)20 7388 7722
Fax: +44 (0)20 7388 7805
www.arktherapeutics.com

BY COURIER

US Securities and Exchange Commission
Division of Corporate Finance
Office of International Corporate Finance
Mail Stop 3-2
450 Fifth Street NW
Washington DC 20549
USA



SUPPL

Ark Therapeutics Group plc, Rule 12g3-2(b) Exemption, File No. 82-34804

To whom it may concern:

Please find enclosed information and/or documents furnished on behalf of Ark Therapeutics Group plc, Rule 12g3-2(b) File No. 82-34804, submitted pursuant to paragraph (b)(1)(iii) of Rule 12g3-2, which information shall not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the US Securities Exchange Act of 1934.

Sincerely,

Nick Plummer
General Counsel & Company Secretary
Ark Therapeutics Group plc

PROCESSED

JUL 18 2005

THOMSON
FINANCIAL

ARK THERAPEUTICS GROUP PLC

FILE NO: 82-34804

1.	DOCUMENTS MADE PUBLIC PURSUANT TO LAWS OF ENGLAND AND WALES SINCE JUNE 9, 2005
1.1	Form 288c Change of Particulars for Director or Secretary in respect of Nicholas Plummer dated June, 21 2005
1.2	Form 288c Change of Particulars for Director or Secretary in respect of Nigel Parker dated June, 21 2005
1.3	Form 288c Change of Particulars for Director or Secretary in respect of Martyn Williams dated June, 21 2005
1.4	Form 288c Change of Particulars for Director or Secretary in respect of Dennis Turner dated June, 21 2005
1.5	Form 288c Change of Particulars for Director or Secretary in respect of Sir Mark Richmond dated June, 21 2005
1.6	Form 288c Change of Particulars for Director or Secretary in respect of David Prince dated June, 21 2005
1.7	Form 288c Change of Particulars for Director or Secretary in respect of Seppo Ylä-Herttuala dated June, 21 2005
1.8	Form 88(2) - Return of Allotment of Shares dated June 24, 2005
1.9	Form 88(2) - Return of Allotment of Shares dated June 28, 2005
2.	DOCUMENTS FILED WITH THE UKLA OR THE LSE (AND MADE PUBLIC THEREBY) SINCE JUNE 9, 2005
2.1	Miscellaneous Notifications filed with The London Stock Exchange
2.1.1	Announcement dated June 14, 2005 regarding Signs Marketing Deal
2.1.2	Announcement dated June 21, 2005 regarding Research Update
2.1.3	Announcement dated June 23, 2005 regarding Director Shareholding
2.1.4	Announcement dated July 7, 2005 regarding Board Appointment
3.	PRESS RELEASES SINCE JUNE 9, 2005
3.1	Press release dated June 14, 2005 regarding Signs Marketing Deal (see 2.1.1 above)
3.2	Press release dated June 21, 2005 regarding Research Update (see 2.1.2 above)
3.3	Press release dated July 7, 2005 regarding Board Appointment (see 2.1.4 above)



288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars

Day	Month	Year
1	0	6
2	0	5

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth

Day	Month	Year
2	4	1
0	1	9
7	0	

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address ††

(enter new address)

Post town

County / Region

Postcode



Country

†† Tick this box if the address shown is a service address for the beneficiary of a Confidentiality Order granted under the provisions of section 723B of the Companies Act 1985

Other change (please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.

† Directors only.

**Delete as appropriate.

Signed

Date

(** director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record..

Tel 0207 388 7722

DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge by Companies House

When you have completed and signed the form please send it to the Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff for companies registered in England and Wales or

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 235 Edinburgh

or LP - 4 Edinburgh 2



Companies House

Partnership

288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars
Day Month Year

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth
Day Month Year

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address ††
(enter new address)

†† Tick this box if the address shown is a service address for the beneficiary of a Confidentiality Order granted under the provisions of section 723B of the Companies Act 1985

Post town

County / Region Postcode

Country

Other change (please specify)

A serving director, secretary etc must sign the form below.

Signed Date

(* director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record..

DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge by Companies House

When you have completed and signed the form please send it to the Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2



288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars

Day	Month	Year
1	0	6
2	0	5

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth

Day	Month	Year
0	5	1
0	5	9
5	1	5
1		

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address †† (enter new address)

†† Tick this box if the address shown is a service address for the beneficiary of a Confidentiality Order granted under the provisions of section 723B of the Companies Act 1985

Post town

County / Region Postcode

Country

Other change (please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.

† Directors only.

**Delete as appropriate.

Signed Date

(* director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record..

Tel 0207 388 7722

DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge by Companies House

When you have completed and signed the form please send it to the Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff for companies registered in England and Wales or

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 235 Edinburgh

or LP - 4 Edinburgh 2



288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars

Day	Month	Year
1	0	6
2	0	5

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth

Day	Month	Year
0	4	1
0	1	9
4	2	

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address †† (enter new address)

†† Tick this box if the address shown is a service address for the beneficiary of a Confidentiality Order granted under the provisions of section 723B of the Companies Act 1985



Post town

County / Region

Postcode

Country

Other change (please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.
† Directors only.
**Delete as appropriate.

Signed

Date

(*director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record..

Tel 0207 388 7722

DX number DX exchange

Companies House receipt date barcode
This form has been provided free of charge by Companies House

When you have completed and signed the form please send it to the Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2



Companies House
part of the

288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript,
or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars
Day Month Year

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth
Day Month Year

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address ††
(enter new address)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985



Post town

County / Region

Postcode

Country

Other change
(please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.
† Directors only.
**Delete as appropriate.

Signed Date

(* director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact
information in the box opposite but if you
do, it will help Companies House to contact
you if there is a query on the form. The
contact information that you give will be
visible to searchers of the public record..

DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

When you have completed and signed the form please send it to the
Registrar of Companies at:
Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland DX 235 Edinburgh
or LP - 4 Edinburgh 2



Companies House
Justice through
transparency

288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript,
or in bold black capitals.

CHWP000

Company Number

4313987

Company Name in full

ARK THERAPEUTICS GROUP PLC

Changes of particulars form

Complete in all cases

Date of change of particulars

Day Month Year
1 0 0 6 2 0 0 5

Name

*Style / Title

*Honours etc

Forename(s)

DAVID NORMAN

Surname

PRINCE

† Date of Birth

Day Month Year
2 4 0 6 1 9 5 1

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address ††

(enter new address)

79 New Cavendish Street

Post town

London

County / Region

Postcode

W1W 6XB

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985



Country

UK

Other change
(please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.

† Directors only.

**Delete as appropriate.

Signed

N. Plummer

Date

21/06/2005

(*director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact
information in the box opposite but if you
do, it will help Companies House to contact
you if there is a query on the form. The
contact information that you give will be
visible to searchers of the public record..

Nick Plummer, Ark Therapeutics Group plc, 79 New Cavendish Street,
London, W1W 6XB

Tel 0207 388 7722

DX number

DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2



Companies House
particulars

288c

CHANGE OF PARTICULARS for director or secretary (NOT for appointment (use Form 288a) or resignation (use Form 288b))

Please complete in typescript,
or in bold black capitals.

CHWP000

Company Number

Company Name in full

Changes of particulars form

Complete in all cases

Date of change of particulars
Day Month Year

Name *Style / Title *Honours etc

Forename(s)

Surname

† Date of Birth
Day Month Year

Change of name (enter new name) Forename(s)

Surname

Change of usual residential address ††
(enter new address)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985



Post town

County / Region Postcode

Country

Other change
(please specify)

A serving director, secretary etc must sign the form below.

* Voluntary details.

† Directors only.

**Delete as appropriate.

Signed Date

(~~director~~ / ~~secretary~~ / ~~administrator~~ / ~~administrative receiver~~ / ~~receiver manager~~ / ~~receiver~~)

You do not have to give any contact information in the box opposite but if you do, it will help Companies House to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record..

Tel 0207 388 7722

DX number DX exchange

Companies House receipt date barcode

This form has been provided free of charge
by Companies House

When you have completed and signed the form please send it to the Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2



Companies House

for the record

88(2)

Return of Allotment of Shares

Please complete in typescript, or in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

Shares allotted (including bonus shares):

Date or period during which shares were allotted <i>(If shares were allotted on one date enter that date in the "from" box)</i>	From			To		
	Day	Month	Year	Day	Month	Year
	2	2	06	2	0	05

Class of shares <i>(ordinary or preference etc)</i>	ORDINARY		
Number allotted	500000		
Nominal value of each share	£0.01		
Amount (if any) paid or due on each share <i>(including any share premium)</i>	0.0001p		

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be treated as paid up			
---	--	--	--

Consideration for which the shares were allotted <i>(This information must be supported by the duly stamped contract or by the duly stamped particulars on Form 88(3) if the contract is not in writing)</i>	

When you have completed and signed the form send it to the Registrar of Companies at:

Companies House receipt date barcode
This form has been provided free of charge by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ DX 33050 Cardiff
For companies registered in England and Wales

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB DX 235
For companies registered in Scotland Edinburgh

Shareholder details	Shares and share class allotted	
Name DR NIGEL PARKER <hr/> Address 79 NEW CAVENDISH STREET, LONDON <hr/> UK Postcode W 1 W 6 X B	Class of shares allotted <hr/> ORDINARY <hr/>	Number allotted <hr/> 500,000 <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> UK Postcode L L L L L L L L	Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed N. Plummer Date 24/06/2005
(A director / secretary / administrator / administrative receiver / receiver manager / receiver) Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer 79 New Cavendish Street London W1W 6XB Tel: 0207 388 7722	<hr/> <hr/> <hr/> <hr/> <hr/>
--	-------------------------------



Companies House
for the record

sent to
28/06/2005

88(2)

Return of Allotment of Shares

Please complete in typescript, or
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

Shares allotted (including bonus shares):

Date or period during which shares were allotted <i>(If shares were allotted on one date enter that date in the "from" box)</i>	From			To		
	Day	Month	Year	Day	Month	Year
	2	3	06	2	0	05

Class of shares <i>(ordinary or preference etc)</i>	ORDINARY	ORDINARY	ORDINARY
Number allotted	7500	3600	3500
Nominal value of each share	£0.01	£0.01	£0.01
Amount (if any) paid or due on each share <i>(including any share premium)</i>	74p	60.5p	50p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be treated as paid up			
--	--	--	--

Consideration for which the shares were allotted <i>(This information must be supported by the duly stamped contract or by the duly stamped particulars on Form 88(3) if the contract is not in writing)</i>	

When you have completed and signed the form send it to
the Registrar of Companies at:

Companies House receipt date barcode
*This form has been provided free of charge
by Companies House.*

Companies House, Crown Way, Cardiff CF14 3UZ
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB
For companies registered in Scotland

DX 235
Edinburgh

Shareholder details	Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED	Class of shares allotted	Number allotted
Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON UK Postcode E 1 4 2 B H	ORDINARY	14,600
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		
Name	Class of shares allotted	Number allotted
Address		
UK Postcode		

Please enter the number of continuation sheets (if any) attached to this form

Signed

Nick Plummer

Date

28/06/2005

~~A director / secretary / administrator / administrative receiver / receiver manager / receiver~~

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

NICK PLUMMER	
79 NEW CAVENDISH STREET	
LONDON W1W W1W 6XB Tel 020 7388 7722	
DX number	DX exchange

Company Ark Therapeutics Group PLC
TIDM AKT
Headline Signs Marketing Deal
Released 07:00 14-Jun-05
Number 5177N

Ark signs marketing deal for Kerraboot® in South Korea

14th June 2005, London UK: Ark Therapeutics Group plc today announces that it has signed an exclusive marketing agreement granting BL&H Co Ltd, a South Korean distributor of healthcare products, sales and marketing rights to Kerraboot® for the South Korean market. Kerraboot® is Ark's novel wound care device for the management of leg and foot ulcers.

Under the terms of the agreement, Ark will receive a double digit royalty on net sales in return for the marketing rights to Kerraboot®. BL&H will purchase the manufactured product from Ark and be responsible for marketing to all sectors of the healthcare community in South Korea, as well as achieving product reimbursement from the Korean regulatory authority.

Lower leg and foot ulceration affects around 1% of the adult population in the developed world(1) and is particularly prevalent amongst the diabetic population where the ulcers can develop rapidly and are particularly difficult to heal. There are an estimated two million diabetics in South Korea, 15% of whom would be expected to have a leg/foot ulcer at any one time.

Kerraboot® provides a new approach to the management of these ulcers, in the form of a novel, non pressurized, boot-like dressing device, which is simple, quick and pain free to change. Kerraboot® facilitates the draining and isolation of exudates such as matrix metalloproteases, which inhibit angiogenesis, from the ulcer. This allows natural growth factors, such as Vascular Endothelial Growth Factors (VEGF), to stimulate healing. In clinical studies of ulcers managed with Kerraboot®, reductions in ulcer sizes of up to 60% have been observed over the four-week study period, with both healthcare professionals and patients expressing a strong preference for Kerraboot® over existing treatments. UK based studies have also shown that management of ulcers with Kerraboot®, which does not involve any additional dressings, can be extremely cost effective.

M Paul Higham, Commercial Director of Ark, commented: "This is our third licensing deal for Kerraboot®, and our first in the Asian market. BL&H has a strong healthcare product distribution capability in South Korea and we look forward to working with them under the terms of this agreement. As we roll out our international commercialisation strategy for Kerraboot®, we expect to announce further licensing deals in 2005."

For further information please contact:

Ark Therapeutics +44 (0)20 7388 7722
Dr Nigel Parker, Chief Executive
Paul Higham, Director of Commercial Development

Financial Dynamics +44 (0)20 7831 3113
David Yates / Lucy Briggs

Notes to Editors

Sources:

1 Briggs M, Nelson EA: Topical agents or dressings for pain in venous leg ulcers; The Cochrane Library, Issue 1, 2002

Ark Therapeutics Group plc

Ark is an emerging healthcare group (the "Group") with one marketed product and three further lead products in late stage clinical development. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a balanced product portfolio targeted at specific unmet clinical needs within vascular disease and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. Ark's products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Company's own means

dependency on any one particular programme or development partner. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets. Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom continue to play leading roles in the Company's research and development programmes.

BL&H Co Ltd

BL&H is a privately owned Korean pharmaceutical company, established in 1999 with the aim of becoming a leading company in the delivery of pharmaceuticals and services that fulfill unmet medical needs of the Korean market. BL&H's product focus is in three main areas; haematology, oncology, and specialist medical devices (wound care). The company is currently focused in the development, marketing, in licensing and distribution of healthcare and orphan drug status products for the Korean market. BL&H's management team has extensive experience in the pharmaceutical/healthcare business within Korea and a thorough understanding of the dynamics of the Korean pharmaceutical market.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.

END

Close

Company Ark Therapeutics Group PLC
TIDM AKT
Headline Research Update
Released 07:00 21-Jun-05
Number 8121N

Ark completes patient enrolment for Vitor™ Phase III study in cancer cachexia

London, UK, 21 June 2005: Ark Therapeutics Group plc (“Ark” and the “Company”), the specialist healthcare group, today announces that patient enrolment for the Phase III study of Vitor™, for the treatment of muscle wasting in cancer (cachexia), has been completed. The company expects preliminary results to be available towards the end of 2005.

The Phase III study is a blinded, placebo controlled, three month study in patients with solid tumours (colon, pancreas, non small cell lung) exhibiting clinical cachexia, defined as involuntary loss of 5% or more of body weight. Ark originally planned to recruit around 160 patients. However a final review by the steering committee found ‘in trial’ cancer deaths, unrelated to the study, were greater than the original estimate had planned for. The Company therefore extended enrolment to 200 patients to adjust for this. The study is being conducted in North America and Europe.

Vitor™ is an oral therapy being developed for the treatment of cachexia (muscle wasting) in cancer, a secondary, often fatal, condition commonly seen in patients with cancer. Between 40 to 90 percent of all cancer patients with solid tumours experience cachexia, and it is particularly prevalent in the common cancers such a lung, stomach and colon cancer. It is estimated that there will be over three million new cases of cancer in Europe and the US in 2005 of which a large majority will involve solid tumours. There are no pharmaceutical products currently approved specifically for the treatment of muscle wasting in cancer and Vitor™ has been awarded Fast Track Designation by the FDA.

Dr. David Eckland, Research and Development Director at Ark, commented: “We are pleased with the progress of the Phase III programme for Vitor™ and with the way recruitment has been finalised with the protocol extension. We look forward to seeing the preliminary results towards the end of the year.”

For further information, please contact:

Ark Therapeutics Group plc
Dr Nigel Parker, CEO

020 7388 7722

Financial Dynamics
Lucy Briggs

020 7831 3113

Notes to Editors

Vitor™ and cachexia in cancer

Vitor™ is an oral small molecule therapy for the treatment of muscle wasting (cachexia), a secondary, often fatal, condition commonly seen in patients with cancer. The active ingredient was originally developed as a treatment for high blood pressure and is currently marketed in Japan and certain countries in Europe. Vitor™ has been shown to up-rate the ability of mitochondria to produce energy. In addition by working on the ubiquitin proteasome pathway, it prevents the breakdown of muscle proteins (actin and myosin) and reverses the impaired muscle protein production, which both occur as a result of the action of chemicals secreted by the cancer tumour and lead to the weight loss.

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the “Group”) addressing high value areas of clear unmet medical need. With one marketed product, Kerraboot®, and three further lead products in late stage clinical development: Vitor™, Cerepro™ and Trinam™, the Group is transitioning from an R&D focused company to a commercial, revenue generating business. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a broad product portfolio targeted at specific unmet clinical needs within vascular disease, wound care and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. Cerepro™ is on track to becoming one of the world’s first commercially available gene-based medicines.

Ark’s products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Company’s own means and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. This strategy has allowed the Group to retain greater value and greater control of clinical development timelines, and to mitigate the risks of dependency on any one particular programme or development

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.

END

Close



Company	Ark Therapeutics Group PLC
TIDM	AKT
Headline	Director Shareholding
Released	08:41 23-Jun-05
Number	9402N

23 June 2005

Ark Therapeutics Group plc Director's Share Dealing

Ark Therapeutics Group plc (LSE: AKT) ("Ark" or the "Company") announces that it was informed on 22 June 2005 that Dr Nigel Parker, CEO, exercised options over 500,000 ordinary Ark shares of 1 pence each on 22 June 2005. These shares, which represent approximately 0.39% of the Company's issued share capital, were subsequently sold at a price of 109 pence per share. Following this transaction, Dr Parker will own 2,886,667 ordinary Ark shares, representing 2.3% of the Company's issued share capital.

The shares sold represent 7% of Dr Parker's total holding of options and shares. Dr Parker has informed the Company that he does not anticipate selling any further shares in the foreseeable future.

- Ends -

END

Close

Company Ark Therapeutics Group PLC
TIDM AKT
Headline Board Appointment
Released 07:00 07-Jul-05
Number 59450.

Ark Therapeutics Plc
Board Appointment

07 July 2005, London UK: Ark Therapeutics Group plc (“Ark” or the “Company”), the specialist healthcare group, today announces the appointment of Dr. Bruce Carter as a non-executive director and member of Ark’s remuneration committee with immediate effect.

Dr Carter, who has over 25 years of pharmaceutical experience, is currently President and Chief Executive Officer of ZymoGenetics Inc (“ZymoGenetics”), the \$1 billion NASDAQ-listed biopharmaceutical company focused on the discovery, development and commercialisation of protein-based therapeutics for the prevention or treatment of human diseases. In 1988 ZymoGenetics was acquired by Novo Nordisk and operated as a wholly owned subsidiary until late 2000, when the company regained its independence through a spinout transaction, which Dr Carter led. Prior to his role as CEO of ZymoGenetics, Dr Carter was Corporate Executive VP and CSO of Novo Nordisk, and was responsible for over 2000 employees and a budget of \$300 million.

Dr Carter has extensive experience at board level. He was on the Board of Management of Novo Nordisk from 1988 to 2000. He is currently on a number of biopharmaceutical boards including Renovis, a biopharmaceutical company developing drugs to treat neurological diseases and disorders and Epigemomics, a company listed on the Deutsche Borse that focuses on improving the prognosis of patients with cancer and other common diseases.

Commenting on this appointment, Dennis Turner, Chairman of Ark, said: “We are delighted to welcome Bruce to Ark. He has an established reputation and is well respected within the international biopharmaceutical industry. His expertise in America will add a significant new dimension to the Board and he will be a great asset to Ark as we advance our pipeline towards commercialisation.”

For further information, please contact:

Ark Therapeutics Group plc
Dr Nigel Parker, CEO 020 7388 7722

Financial Dynamics
Lucy Briggs 020 7831 3113

Notes to Editors

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the “Group”), addressing high value areas of clear unmet medical need. With one marketed product, Kerraboot®, and three further lead products in late stage clinical development: Vitor™, Cerepro™ and Trinam™, the Group is transitioning from an R&D focused company to a commercial, revenue generating business. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a broad product portfolio targeted at specific unmet clinical needs within vascular disease, wound care and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. Cerepro™ is on track to becoming one of the world’s first commercially available gene-based medicines.

Ark’s products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Company’s own means and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. This strategy has allowed the Group to retain greater value and greater control of clinical development timelines, and to mitigate the risks of dependency on any one particular programme or development partner. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of

believes, estimates, expects, aims, intends, will, can, may, anticipates, would, should, could or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.

END

Close